Komiya T, Hosono Y, Hirashima T, Masuda N, Yasumitsu T, Nakagawa K, Kikui M, Ohno A, Fukuoka M, Kawase I
Departments of Internal Medicine, Pathology, and Surgery, Osaka Prefectural Habikino Hospital, Habikino City, Osaka 583, Japan.
Clin Cancer Res. 1997 Oct;3(10):1831-5.
Although p21 WAF1/Cip1 expression has been detected immunohistochemically in non-small cell lung cancer (NSCLC), the associations between p21 expression and clinical characteristics are unknown. To determine the association between p21 expression and clinical features, p21 expression was immunohistochemically analyzed in paraffin-embedded tumor samples from 137 patients with curatively resected NSCLC. p21 expression, indicating normal p21 function, was detected in 48 (35.0%) of the 137 patients with curatively resected NSCLC and was detected more frequently in patients with stage I or II disease (40.2%) than in those with stage IIIA disease (22.5%; P = 0.0483). There was no difference in the positive rate between squamous cell carcinoma [SCC; 15 of 48 (31.3%)] and adenocarcinoma [30 of 77 (39.0%)]. For SCC, patients with tumors expressing p21 survived longer than did those with tumors negative for p21 expression; however, the corresponding survival time was not significant for adenocarcinoma. On the other hand, p53 expression, detected in 58 (42.3%) of these patients, did not act as any predictor for prognosis in either SCC or adenocarcinoma. Our findings suggest that the presence of p21 expression is associated with favorable prognosis in SCC and may be useful in obtaining candidates for adjuvant therapies from among patients with SCC.
虽然已通过免疫组织化学方法在非小细胞肺癌（NSCLC）中检测到p21 WAF1/Cip1的表达，但p21表达与临床特征之间的关联尚不清楚。为了确定p21表达与临床特征之间的关联，对137例接受根治性切除的NSCLC患者石蜡包埋的肿瘤样本进行了p21表达的免疫组织化学分析。在137例接受根治性切除的NSCLC患者中，有48例（35.0%）检测到p21表达，提示p21功能正常，且在Ⅰ期或Ⅱ期疾病患者中检测到的频率（40.2%）高于ⅢA期疾病患者（22.5%；P = 0.0483）。鳞状细胞癌[SCC；48例中有15例（31.3%）]和腺癌[77例中有30例（39.0%）]的阳性率没有差异。对于SCC，p21表达阳性的肿瘤患者比p21表达阴性的肿瘤患者存活时间更长；然而，腺癌患者相应的生存时间差异无统计学意义。另一方面，在这些患者中有58例（42.3%）检测到p53表达，p53表达在SCC或腺癌中均不能作为预后的预测指标。我们的研究结果表明，p21表达的存在与SCC的良好预后相关，可能有助于从SCC患者中筛选辅助治疗的候选者。
